Download MendeleyHigh Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
Garcha, H.K., Nawar, N., Sorger, H., Erdogan, F., Aung, M.M.K., Sedighi, A., Manaswiyoungkul, P., Seo, H.S., Schonefeldt, S., Poloske, D., Dhe-Paganon, S., Neubauer, H.A., Mustjoki, S.M., Herling, M., de Araujo, E.D., Moriggl, R., Gunning, P.T.(2022) Pharmaceuticals (Basel) 15
- PubMed: 36355493
- DOI: https://doi.org/10.3390/ph15111321
- Primary Citation of Related Structures:
7UK2 - PubMed Abstract:
NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, including T-cell lymphomas. This study represents exploratory findings of HDAC6 inhibition in NKTCL and γδ T-NHL through a second-generation inhibitor NN-429. With nanomolar in vitro HDAC6 potency and high in vitro and in cellulo selectivity for HDAC6, NN-429 also exhibited long residence time and improved pharmacokinetic properties in contrast to older generation inhibitors. Following unique selective cytotoxicity towards γδ T-NHL and NKTCL, NN-429 demonstrated a synergistic relationship with the clinical agent etoposide and potential synergies with doxorubicin, cytarabine, and SNS-032 in these disease models, opening an avenue for combination treatment strategies.
- Department of Chemical and Physical Sciences, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON L5L 1C6, Canada.
Organizational Affiliation:
